Dry Powder Inhalers - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The dry powder inhalers market size is projected to expand from USD 24.44 billion in 2025 and USD 25.64 billion in 2026 to USD 32.71 billion by 2031, registering a CAGR of 4.97% between 2026 and 2031. This report is segmented by Product Type (Capsule-Based Dry Powder Inhalers, Blister-Based Dry Powder Inhalers, and More), by Drug Class (Inhaled Corticosteroids and More), by Indication (Asthma and More), by Device Lifestyle (Reusable Inhalers and More), by Distribution Channel (Hospital Pharmacies and More), Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Dry Powder Inhalers Market Trends and Insights

Rising Asthma, COPD, and Cystic Fibrosis Burden

The dry powder inhalers market benefits from a durable need for long-term respiratory treatment. Continued particulate exposure in South and East Asian cities increases the population at risk of COPD. Urban allergen exposure also supports asthma incidence among younger patients in Latin America and Africa. The 2026 review of 44 randomized controlled trials involving 24,710 participants found that dry powder inhalers had equivalent efficacy and safety to pressurized metered-dose inhalers for asthma maintenance and COPD treatment. This evidence gives clinicians more flexibility to select a device based on patient use, treatment goals, and environmental considerations. Cystic fibrosis adds a long-duration source of demand because longer survival with CFTR modulators can extend the period during which patients use inhaled antibiotics and mucolytics.

Preference for Propellant-Free Pulmonary Delivery

The dry powder inhalers market is increasingly affected by healthcare decarbonization programs. Health systems must consider emissions, clinical suitability, device training, and medicine availability when they revise inhaler formularies. This creates a more structured decision process than a simple switch between inhaler formats. A 2025 study found that 100,000 dispensed pressurized metered-dose inhalers generated 1,000 to 1,100 tonnes of carbon dioxide equivalent emissions, compared with less than 55 tonnes for an equivalent volume of dry powder inhalers. This difference is influencing procurement and prescribing discussions in European health systems. National data cited in the draft showed that multi-dose dry powder inhalers accounted for 87% of inhalers dispensed in Sweden. AstraZeneca received UK approval in May 2025 for Trixeo Aerosphere with a near-zero global warming potential propellant, illustrating how sustainability requirements are also changing pressurized-device development. European procurement policies through 2031 can favor manufacturers that can demonstrate low-emission respiratory delivery and dependable device performance.

Patient Inspiratory-Flow Limitations

The dry powder inhalers market remains limited by the physical ability of some patients to use these devices effectively. This limitation makes patient assessment and device training important parts of treatment selection. It can also require clinicians to retain alternative inhaler options for people whose inspiratory flow is inadequate. Advanced COPD and older age can reduce the peak inspiratory flow needed for consistent drug deposition. A 2025 study examined preliminary bronchodilation and aerosol delivery in COPD patients with suboptimal peak inspiratory flow, highlighting the challenge for standard DPI devices. The issue can be more pronounced in Asia-Pacific and the Middle East and Africa, where COPD may be diagnosed later. Poor device fit can create a difference between clinical trial performance and real-world treatment use. The constraint will remain until low-resistance devices can preserve adequate fine-particle delivery for a wider range of patients.

Other drivers and restraints analyzed in the detailed report include:

• Expansion of Home-Based Respiratory Care
• Growth of High-Payload and Inhaled Biologic Programs
• Complex Drug-Device Bioequivalence Requirements

Segment Analysis

Blister-based devices held 36.18% revenue share in 2025. Precise dose metering and established manufacturing systems support their use across small-molecule and peptide-based products. Multi-dose blister devices fit fixed-dose combinations that are increasingly used in COPD and asthma treatment. Their dose-tracking potential also supports adherence programs when paired with digital services. Capsule-based inhalers retain demand in price-sensitive Asia-Pacific and South American settings. These devices can offer lower device costs and compatibility with generic medicines.

Cartridge-based formats are projected to expand at a 6.12% CAGR through 2031. Their architecture can support higher drug payloads for combination regimens and inhaled biologics. Spray-drying process design, including outlet-temperature management, can help retain protein bioactivity in these applications. Reservoir devices continue to serve patients who value multi-dose convenience. However, they face pressure from blister devices that may provide more accurate dose tracking. Disposable devices are used where infection-control protocols or short antibiotic courses make single-patient use more appropriate.

Inhaled corticosteroid combination therapies accounted for 42.16% of the dry powder inhalers market share in 2025. Their position reflects the central role of ICS and long-acting beta agonist combinations in asthma maintenance. Global treatment guidelines have supported their continued use as foundational therapy. Patients with uncontrolled disease can progress through structured treatment pathways toward more intensive combinations. Standalone inhaled corticosteroids face pressure from step-down approaches when patients have stable symptoms. Combination products also help manufacturers link a medicine portfolio with a familiar device platform.

Long-acting muscarinic antagonists are forecast to expand at a 6.34% CAGR through 2031. Their use is extending from COPD maintenance toward triple-combination treatment in asthma. This shift increases the clinical relevance of LAMA-containing dry powder inhalers beyond their historical COPD base. Short-acting beta agonists are also beginning to move from pressurized formats into dry powder devices in sustainability-focused formularies. The remaining drug class includes inhaled antibiotics, antifungals, and antiviral agents. These products show how pulmonary delivery can address specialized respiratory and systemic treatment needs.

Complete Report Scope:

• By Product Type
  • Capsule-Based Dry Powder Inhalers
  • Blister-Based Dry Powder Inhalers
  • Reservoir-Based Dry Powder Inhalers
  • Cartridge-Based Dry Powder Inhalers
  • Disposable Dry Powder Inhalers
• By Drug Class
  • Inhaled Corticosteroids
  • Short-Acting Beta Agonists
  • Long-Acting Beta Agonists
  • Long-Acting Muscarinic Antagonists
  • Inhaled Corticosteroid Combination Therapies
  • Others (Antibiotics, Antiviral Agents, etc.)
• By Indication
  • Asthma
  • Chronic Obstructive Pulmonary Disease
  • Cystic Fibrosis
  • Bronchitis
  • Pulmonary Arterial Hypertension
  • Others (Pulmonary Infections, Diabetes, etc.)
• By Device Lifecycle
  • Reusable Inhalers
  • Disposable Inhalers
  • Single-Use Inhalers
  • Recyclable and Circular-Design Inhalers
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others (Specialty Pharmacies, Mail-Order Pharmacies etc.)
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 38.11% of the dry powder inhalers market share in 2025. Premium branded platforms, payer coverage for specialty respiratory therapies, and regulatory pathways for digital device additions support regional demand. In April 2026, CMS expanded Medicare coverage for home non-invasive ventilation for COPD, reinforcing the policy setting for home respiratory management. Connected inhaler programs can integrate therapy into remote care practices and create practical switching barriers for established brands. The United States benefits from deep specialty reimbursement pathways. Canada and Mexico add steady demand as formulary coverage for combination therapies broadens.

The dry powder inhalers market in Europe has a distinct policy basis because environmental considerations shape prescribing and procurement. Health services must assess whether a proposed device remains clinically appropriate for each patient while pursuing lower-emission treatment options. A 2024 analysis estimated annual European emissions from pressurized metered-dose inhalers at 4.0 Mt of carbon dioxide equivalent and indicated that replacement with dry powder inhalers could lower the total to 0.60 Mt. Sweden, the Netherlands, Germany, and the United Kingdom are using this type of evidence in inhaler guidance. Germany, the United Kingdom, France, Italy, and Spain remain mature, high-volume markets. The rest of Europe can benefit as generic penetration improves and device suppliers refresh platforms for EU medical-device requirements.

The dry powder inhalers market in Asia-Pacific is forecast to expand at a 6.93% CAGR through 2031. This growth profile reflects a mix of price-sensitive volume needs, branded combination therapies, growing diagnoses, and a continuing need to strengthen distribution outside major urban centers. China’s 2025 national reimbursement list expansion included 18 additional inhaled therapies and reduced out-of-pocket costs for maintenance treatment. In July 2026, Sino Biopharmaceutical expanded its exclusive collaboration with GSK to commercialize Trelegy Ellipta and Anoro Ellipta in China. India’s respiratory care setting is supported by Ayushman Bharat coverage, although rural distribution gaps still restrict penetration outside major cities. Japan, South Korea, and Australia have stronger conditions for connected inhaler adoption due to telehealth policy support.

List of Companies Covered in this Report:

• AptarGroup, Inc.
• AstraZeneca
• Berry Global, Inc.
• Bespak Limited
• Boehringer Ingelheim
• Chiesi Farmaceutici
• Cipla
• Elpen S.A.
• GlaxoSmithKline
• H&T Presspart Manufacturing Ltd.
• Hovione Holding S.A.
• Lupin
• MannKind
• Nemera Development S.A.S.
• Novartis
• Orion
• Otsuka
• Sun Pharmaceuticals Industries
• Teva Pharmaceutical Industries
• Vectura Group Limited
• Viatris

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support